Insight

Daniel Chen: After a decade of immense progress for patients with cancer immunotherapy we are excited to publish a 10-year update, reflecting the complexity in the TME.

Photo from Daniel Chen/LinkedIn

Oct 14, 2023, 16:32

Daniel Chen: After a decade of immense progress for patients with cancer immunotherapy we are excited to publish a 10-year update, reflecting the complexity in the TME.

Daniel Chen, Founder of Engenuity Life Sciences, shared on LinkedIn:

“We wrote the Cancer Immunity Cycle in 2013– and the scientific framework continues to hold up to time. After a decade of immense progress for patients with cancer immunotherapy we are excited to publish a 10Y update, reflecting the complexity in the TME.

It was an enormous effort to put together- and an incredible sprint at the end to finish. A big thanks to my co-authors Ira Mellman, Tom Powles, Shannon Turley.

And Thank You to Cell Press immunity Fabiola Rivas, Allison Bruce and all the authors that contributed to this special issue of Immunity!”

For the article click here.
Source: Daniel Chen/LinkedIn

Allison Bruce cancer Cancer Immunity Cycle Cell Press Daniel Chen Fabiola Rivas immunotherapy Ira Mellman OncoDaily Oncology Shannon Turley Tom Powles tumor microenvironment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage